Enjoy complimentary customisation on priority with our Enterprise License!
The narcolepsy drugs market share is expected to increase to USD 1.60 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9.1%.
This narcolepsy drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers narcolepsy drugs market segmentation by type (narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy) and geography (North America, Europe, Asia, and Rest of World (ROW)). The narcolepsy drugs market report also offers information on several market vendors, including Alkermes Public Ltd. Co., Apotex Inc., Aurobindo Pharma Ltd., Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., BIOPROJET, Cadila Pharmaceuticals Ltd., Don Valley Pharma, Graymark Healthcare Inc., Jabs Biotech Pvt. Ltd., Jazz Pharmaceuticals Plc, Luckys Pharma Pvt. Ltd., Midas Pharma GmbH, Orbion Pharmaceuticals Pvt. Ltd., Shionogi and Co. Ltd., Somacare, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and XWPharma Ltd. among others.
Download the Free Report Sample to Unlock the Narcolepsy Drugs Market Size for the Forecast Period and Other Important Statistics
The rising product launches and clinical trials is notably driving the narcolepsy drugs market growth, although factors such as lack of awareness may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the narcolepsy drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Narcolepsy Drugs Market Driver
The rising product launches and clinical trials is one of the key factors driving the narcolepsy drugs market growth. Rising cases of narcolepsy have led vendors to launch new drugs to meet the demand for the treatment and the following are some of the instances:
The above-mentioned instances of product launches and clinical trials are expected to drive market growth during the forecast period.
Key Narcolepsy Drugs Market Trend
Key Narcolepsy Drugs Market Challenge
This narcolepsy drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global narcolepsy drugs market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the narcolepsy drugs market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the narcolepsy drugs market encompasses successful business strategies deployed by the key vendors. The narcolepsy drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The narcolepsy drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the narcolepsy drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
44% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the narcolepsy drugs market in North America. Market growth in this region will be slower than the growth of the market in Asia.
The high per capita pharmaceutical expenditure will facilitate the narcolepsy drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The COVID-19 pandemic in 2020 had a negative impact on the narcolepsy drugs market in North America. However, the market recovered since vaccine distribution in 2021 as it decreased the number of COVID-19 cases in the region. Therefore, the resumption of manufacturing operations of narcolepsy drugs and the increasing awareness of the disease is expected to drive market growth in North America during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The narcolepsy drugs market share growth by the narcolepsy with cataplexy segment will be significant during the forecast period. The onset of narcolepsy with cataplexy is usually during the teenage and young adulthood years and persists throughout the lifetime. Pathophysiological studies have shown that the disease is caused by the early loss of neurons in the hypothalamus that produce hypocretin, a wakefulness-associated neurotransmitter, present in cerebrospinal fluid. The treatment includes stimulant drugs to suppress daytime sleepiness, antidepressants for cataplexy, and gamma-hydroxybutyrate for both symptoms. Moreover, the rising cases of narcolepsy with cataplexy will boost the market growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the narcolepsy drugs market size and actionable market insights on post COVID-19 impact on each segment.
Narcolepsy Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.1% |
Market growth 2022-2026 |
$ 1.60 billion |
Market structure |
Fragmented |
YoY growth (%) |
8.5 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 44% |
Key consumer countries |
US, Canada, Germany, UK, and France |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Alkermes Public Ltd. Co., Apotex Inc., Aurobindo Pharma Ltd., Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., BIOPROJET, Cadila Pharmaceuticals Ltd., Don Valley Pharma, Graymark Healthcare Inc., Jabs Biotech Pvt. Ltd., Jazz Pharmaceuticals Plc, Luckys Pharma Pvt. Ltd., Midas Pharma GmbH, Orbion Pharmaceuticals Pvt. Ltd., Shionogi and Co. Ltd., Somacare, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and XWPharma Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.